Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kanako KAWAGUCHI"'
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 83:473-478
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1adfbfee9619cd450cdcf04ae10c2a7
https://doi.org/10.3919/jjsa.83.473
https://doi.org/10.3919/jjsa.83.473
Autor:
Norihiro Hokimoto, Risa Terasawa, Tsutomu Takashima, Takashi Morimoto, Shintaro Michishita, Hirotaka Morishima, Shinichiro Kashiwagi, Junna Sakane, Yukihiro Nishida, Mitsuhiko Iwamoto, Satoru Noda, Nobuki Matsunami, Toshikatsu Nitta, Hiruya Fujioka, Kosei Kimura, Satoru Tanaka, Ayana Ikari, Nayuko Sato, Toshihiro Kobayashi, Yukie Tauchi, Naofumi Oda, Yuka Asano, Kanako Kawaguchi
Publikováno v:
Cancer Research. 80:P2-16
Background: Neoadjuvant anti-HER2 target agents combined with anthracycline and taxane is now considered a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A less toxic, non-anthracycline regimen has been c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfc4431e27be5f2aad16c9339be6aa51
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-32
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-32
Publikováno v:
Ceramics International. 44:4462-4466
Porous CaAl12O19 ceramics attract much attention toward many potential applications, such as high-temperature filters, catalyst supports, and lightweight structural materials at high temperatures. In this study, we have focused on the reactive sinter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4acfa54f611e6e28fc1e5d9db31cfb59
https://doi.org/10.1016/j.ceramint.2017.11.138
https://doi.org/10.1016/j.ceramint.2017.11.138
Autor:
Kanako Kawaguchi, Hiroya Fujioka, Kosei Kimura, Yoshihumi Narumi, Risa Terasawa, Mitsuhiko Iwamoto, Izumi Morinaga, Yoshitaka Kurisu, Erika Hattori, Masako Yuki, Kazuhisa Uchiyama
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 26:195-199
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::025df4eb49873518adb4d4a0bc135cee
https://doi.org/10.3804/jjabcs.26.195
https://doi.org/10.3804/jjabcs.26.195
Autor:
Nayuko Sato, Kosei Kimura, Yuka Asano, Yukihiro Nishida, Shinichiro Kashiwagi, Tsutomu Takashima, Takashi Morimoto, Ayana Ikari, Toshihiro Kobayashi, Satoru Noda, Yukie Tauchi, Hiroya Fujioka, Naofumi Oda, Mitsuhiko Iwamoto, Nobuki Matsunami, Satoru Tanaka, Risa Terasawa, Hirotaka Morishima, Junna Sakane, Kanako Kawaguchi, Toshikatsu Nitta, Norihiro Hokimoto, Shintaro Michishita
Publikováno v:
Cancer chemotherapy and pharmacology. 83(6)
Neoadjuvant trastuzumab combined with anthracycline and taxane is now considered a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A less toxic, non-anthracycline regimen has been considered as a treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee25ccfff740b8602c4ef7814942b8a9
https://pubmed.ncbi.nlm.nih.gov/30963212
https://pubmed.ncbi.nlm.nih.gov/30963212
Autor:
Kanako Kawaguchi, Nayuko Sato, Hiroya Fujioka, Kazuhisa Uchiyama, Risa Terasawa, Junna Matsuda, Nodoka Umezaki, Kosei Kimura, Mitsuhiko Iwamoto, Satoru Tanaka
Publikováno v:
Molecular and Clinical Oncology. 5:385-390
The purpose of this study was to retrospectively analyze the feasibility of outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer. A total of 131 consecutive patients with breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9be54769104a09501746cca50e9d55de
https://doi.org/10.3892/mco.2016.992
https://doi.org/10.3892/mco.2016.992
Autor:
Kosei Kimura, Takashi Morimoto, Mitsuhiko Iwamoto, Kanako Kawaguchi, Risa Terasawa, Hiroyuki Ogura, Nobuki Matsunami, Satoru Tanaka, Daigo Yamamoto, Katsuhide Yoshidome, Hiroya Fujioka, Toshikatsu Nitta, Kazuhisa Uchiyama, Yuko Takahashi
Publikováno v:
Cancer chemotherapy and pharmacology. 81(5)
Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor receptor 2 (HER2)-negative MBC are still limited. Therefore, we conduct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d94c2f0d871a19490b12a9ec63e0520
https://pubmed.ncbi.nlm.nih.gov/29594360
https://pubmed.ncbi.nlm.nih.gov/29594360
Autor:
Hiyoya Fujioka, Kanako Kawaguchi, Kazuhisa Uchiyama, Yuko Takahashi, Saki Maezawa, Kosei Kimura, Nodoka Umezaki, Tomo Tominaga, Ayana Ikari, Nayuko Sato, Satoru Tanaka, Mitsuhiko Iwamoto, Risa Terasawa, Junna Matsuda
Publikováno v:
Anticancer research. 36(12)
Background: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1373ec52ae56abe9de467fbdca38ca9b
https://pubmed.ncbi.nlm.nih.gov/27919974
https://pubmed.ncbi.nlm.nih.gov/27919974
Autor:
Risa, Terasawa, Mitsuhiko, Iwamoto, Satoru, Tanaka, Kosei, Kimura, Yuko, Takahashi, Hiroya, Fujioka, Nayuko, Sato, Kanako, Kawaguchi, Ayana, Ikari, Saki, Maezawa, Tomo, Tominaga, Junna, Matsuda, Nodoka, Umezaki, Kazuhisa, Uchiyama
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 43(6)
Squamous cell carcinoma(SCC)of the breast is a rare disease. We encountered a case of SCC of the breast that relapsed in the early postoperative period and rapidly progressed thereafter. A 38-year-old woman visited our hospital presenting with a tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e974c435ef9a7a2221d07fa76b6eeec8
https://pubmed.ncbi.nlm.nih.gov/27306813
https://pubmed.ncbi.nlm.nih.gov/27306813
Autor:
C Koda, Hiroya Fujioka, Risa Terasawa, Kazuhisa Uchiyama, Kosei Kimura, Kanako Kawaguchi, Nayuko Sato, Mitsuhiko Iwamoto, Satoru Tanaka
Publikováno v:
Cancer Research. 77:OT1-02
Background: Neoadjuvant chemotherapy plus trastuzumab results in a 30% to 50% pathologic complete response (pCR) rate in HER-2 positive breast cancer and has been associated with improved therapeutic outcomes. Thus, the pCR rate can be useful in eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7560f99c4fcccd9d459e251d100adf43
https://doi.org/10.1158/1538-7445.sabcs16-ot1-02-01
https://doi.org/10.1158/1538-7445.sabcs16-ot1-02-01